Politwoops
Explore the Tweets They Didn't Want You to See
Politwoops tracks deleted tweets by public officials, including people currently in office and candidates for office.
Politwoops tracks deleted tweets by public officials, including people currently in office and candidates for office. If you think we're missing someone, please email us with their name, state, political party, office they hold or are seeking and, of course, their Twitter handle.
Are your deleted tweets displayed here but you think they shouldn't be? Here's how to let us know.
Yesterday, I stood with federal workers in South Jersey that have been affected by the government shutdown. I will continue to vote to open the government but I will also work with anyone who wants to end this mess. https://t.co/HPX25aOz5x
RT @cubanlefse: @RepSamGraves and staff thank you for meeting with us on behalf of @SSFFoundation16 and @uscgcpoa and talking to us about #PayOurCoasties #teamUSCGhHillDay https://t.co/jRRO6yUndT
SteveFDA (R-D.C.)
@SGottliebFDA
During the lapse in funding, #FDA continues to advance certain policy, consistent with what's permissible under law. Like today’s guidance, supported by carryover user-fees.
SteveFDA (R-D.C.)
@SGottliebFDA
@dgingery These were guidance documents that, generally, were in very advanced stages of development, and close to being releasing before the lapse in appropriations. It's the case that new guidance development is being affected by the lapse.
auctnr1 (R-Mo.)
@auctnr1
RT @seanhannity: Watch ? https://t.co/A9yJIQV9Ue
SteveFDA (R-D.C.)
@SGottliebFDA
RT @fdalawblog: New FDA Guidance: Labeling for Human Prescription Drug and Biological Products Approved Under the Accelerated Approval Regulatory Pathway Guidance for Industry - https://t.co/PCfFXayaOS
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAMedia: Statement from FDA Commissioner @SGottliebFDA and Jeff Shuren, M.D., Director of the Center for Devices and Radiological Health, on latest steps to strengthen FDA’s 510(k) program for premarket review of medical devices https://t.co/sRfZy6UqT3
SteveFDA (R-D.C.)
@SGottliebFDA
Appreciate the chance to join thousands of my colleagues from CDER and CBER today to discuss the impacts of the #shutdown on our continuing operations, and the steps we’re taking to continue to fulfill our mission and our mandate to the American people. https://t.co/BmtrDuR687
SteveFDA (R-D.C.)
@SGottliebFDA
Today, #FDA finalized a policy on labeling for drugs approved under accelerated approval, reflecting the more frequent use of this pathway for drugs used in certain clinical settings. https://t.co/xtNGW1wkj0
SteveFDA (R-D.C.)
@SGottliebFDA
The accelerated approval pathway facilitates earlier approval of drugs that treat serious conditions and the clinical community has garnered a greater understanding of how certain surrogate endpoints inform clinical practice.
Are your deleted tweets displayed here but you think they shouldn't be? Here's how to let us know.